Skip to main content
. 2016 Mar 30;7(18):26724–26738. doi: 10.18632/oncotarget.8494

Table 3. COSMIC identified SNV from matched tumor samples derived from blood or biopsy.

ID E/P/H ctcDNA ccfDNA FFPE 1 FFPE 2
C293-001 +/+/− X X X
C293-002 −/−/+ TP53; p.E285K X QNS tissue
C293-003 −/−/+ X X X
C293-004 +/−/− X PIK3CA;p.E542K PIK3CA;p.E542K PIK3CA;p.E542K
C293-005 +/−/+ X PIK3CA; p.V344G
ERBB2; p.V777L
PIK3CA; p.V344G
ERBB2; p.V777L
C293-006 −/−/− X TP53;p.H193R TP53;p.H193R
C293-007 −/−/− X X KRAS; V14I
C293-008 NA X TP53; p.S215R QNS tissue
C293-009 +/+/Eq X X X
C293-010 +/−/+ TP53; p.Y163D TP53; p.Y163D QNS Tissue
C293-011 −/−/− X TP53; p.R175H TP53; p.R175H
C293-012 +/−/− X X X
C293-013 +/+/− X QNS DNA PIK3CA; p.H1047R X
C293-014 +/+/Eq X TP53; p.M246I X
C293-015 −/−/− X X X
C293-016 −/−/+ PIK3CA; p.E545K X QNS Tissue
C293-018 +/−/− PIK3CA; p.H1047R PIK3CA; p.H1047R QNS DNA PIK3CA; p.H1047R
C293-019 +/+/− X X IDH2; p.R140Q
C293-020 −/−/− X X X
C293-021 +/+/− X GNAQ; Q209K X
C293-022 +/+/− X X PIK3CA; p.E545K
C293-023 −/+/Eq TP53; p.R175H TP53; p.R175H TP53; p.R175H
C293-024 +/−/− X PIK3CA; p.H1047R X PIK3CA; p.H1047R
C293-025 +/−/− X X X
C293-026 +/−/Eq PIK3CA; p.H1047R PIK3CA; p.H1047R TP53; p.C182Y APC; p.Q1447*
TP53; p.G108S
PIK3CA; p.H1047R
C293-027 +/+/− TP53; p.H178P X X
C293-028 +/−/− X X QNS DNA
C293-029 −/−/+ X TP53; p.E286K QNS DNA
C293-030 +/+/− X X ERBB2; V777L
C293-031 +/+/− X X X
C293-032 −/−/− X TP53; p.Y107* X
C293-033 +/+/− TP53; p.C176F TP53; p.C176F
TP53; p.C176S
TP53; p.C176F

Most recent hormonal (ER/PR) and Her2 status is included where available (E/P/H) and indicated as present (+), absent (-), or equivocal (Eq). Alterations are indicated by the target gene and the predicted impact. Samples with no detectable alteration at the limit of detection are indicated by X. Samples that were quantity not sufficient (QNS) are indicated.